Neurocrine Biosciences Ord Shs (NBIX)

$120.16 2.85 (2.32%)

19:52 EDT NBIX Stock Quote Delayed 30 Minutes

Volume:

Previous Close $120.16

Market Cap 10.80B

PE Ratio -100.97

EPS -1.19

Volume (Avg. Vol.) 1.57M

Day's Range 119.20 - 126.71

52-Week Range 72.14 - 136.26

Dividend & Yield N/A (N/A)

NBIX Stock Predictions, Articles, and Neurocrine Biosciences Ord Shs News

From InvestorPlace
From the Web

7 Beautiful Biotech Stocks to Buy Here

By Louis Navellier and the InvestorPlace Research Staff, Editor, Growth Investor Apr 24, 2020

Covid-19 has put the biotech stocks in the spotlight, but treatments for the pandemic are far from the only reason investors should watch this space.

8 Stocks to Buy That Are Growing Faster Than Amazon

By James Brumley, InvestorPlace Feature Writer Jul 19, 2019

Neurocrine Biosciences, Facebook and Etsy are just some of the stocks to buy if you want growth because they're outpacing Amazon.

10 Smart Money Stocks to Buy for the Rest of the Year

By Harriet Lefton, Writer, TipRanks Jan 29, 2019

These 10 smart money stocks to buy have significant support from top analysts. Here's why each should help you flourish throughout the rest of the year.

6 Stocks Set for Monster Growth in 2019

By Harriet Lefton, Writer, TipRanks Jan 28, 2019

Looking for stocks to buy now? These six companies are among the best stocks to invest in for their immaculate record from the Street's top analysts. Here's why:

5 Biotech Stocks That Could Face M&A Next!

By Aaron Levitt, InvestorPlace Contributor Jan 10, 2019

Big biotech buyouts have already started happening. These five biotech stocks could be the next to go.

Neurocrine Biosciences Is a Pharma Stock to Watch

By Louis Navellier, Editor, Growth Investor Jan 7, 2019

Biopharma company Neurocrine isn't letting a setback with one of its drugs stop it. Here's what to know about NBIX stock.

Compare Brokers

5 Pharma Stocks to Stay Away From

By Will Healy, InvestorPlace Contributor Nov 12, 2018

With an aging population, pharma stocks can be a very profitable investments. These 5 biotechs probably aren't.

10 Fast-Growing Stocks With Monster Catalysts This Summer

By James Brumley, InvestorPlace Feature Writer Jul 11, 2018

A slow summer puts a premium on fast-growing stocks, and even more so on names that are headed into some splashy headlines.

5 Biotech Stocks That Could Be the Next Amgen

By Aaron Levitt, InvestorPlace Contributor Jun 27, 2018

Looking for the next big biotech stock? Skip the clinical ones and focus on those with approved drugs. Here are 5 biotech stocks to buy today.

3 Stocks to Watch on Wednesday: Tesla, Inc. (TSLA), Delta Air Lines, Inc. (DAL) and Neurocrine Biosciences, Inc. (NBIX)

By Karl Utermohlen, InvestorPlace Writer Apr 12, 2017

Delta Air Lines (DAL) pops on solid Q1 earnings, a major investor questions Tesla's (TSLA) board and Neurocrine Biosciences (NBIX) is flying on an FDA approval.

10 Small-Cap Stocks That Could Double in the Next 3 Months

By James Brumley, InvestorPlace Feature Writer Mar 21, 2017

These small-cap stocks all have the potential to dish out misery, but if things work out just right, look out above.

40 Biotechnology Stocks to Sell Now

By Portfolio Grader Dec 12, 2016

This week, the overall grades of 40 Biotechnology stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").

Compare Brokers